• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Minerva Neurosciences Inc

    10/22/24 7:09:49 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NERV alert in real time by email
    DEFA14A 1 d843316ddefa14a.htm DEFA14A DEFA14A

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☒   Filed by a party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under § 240.14a-12

    MINERVA NEUROSCIENCES, INC.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11


    LOGO

    Your Vote Counts! MINERVA NEUROSCIENCES, INC. 2024 Annual Meeting of Stockholders to be held on December 5, 2024 at 9:30 A.M. Eastern Time Vote by December 4, 2024 11:59 PM ET MINERVA NEUROSCIENCES, INC. 1500 DISTRICT AVE BURLINGTON, MA 01803 V57511-P18410 You invested in MINERVA NEUROSCIENCES, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the 2024 Annual Meeting of Stockholders to be held on December 5, 2024 at 9:30 A.M. Eastern Time at www.virtualshareholdermeeting.com/NERV2024. Get informed before you vote View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to November 21, 2024. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. There is no charge for requesting a copy of the voting material(s). The record date for the Annual Meeting is October 7, 2024. Only stockholders of record at the close of business on that date may vote at the Annual Meeting or any adjournment or postponement thereof. For the ten days prior to the Annual Meeting, a list of our stockholders as of the close of business on the record date and entitled to vote at the Annual Meeting will be available for examination during normal business hours by any stockholder of record for a legally valid purpose at our principal executive offices or by emailing us at [email protected]. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* December 5, 2024 9:30 AM EDT Virtually at: www.virtualshareholdermeeting.com/NERV2024 *Please check the meeting materials for any special requirements for meeting attendance.


    LOGO

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This communication presents only an overview of the proposals being presented at the upcoming stockholder meeting as described in the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.ProxyVote.com or easily request a paper copy (see reverse side). Please follow the instructions on the reverse side to vote on these important matters. We encourage you to access and review all of the important information contained in the proxy materials before voting. Board Voting Items Recommends 1. To elect two Class I directors each to hold office until 2027 Annual Meeting of Stockholders. Nominees: For 01) Hans Peter Hasler 02) Dr. Remy Luthringer 2. To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the For accompanying proxy statement. 3. To ratify the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for For its fiscal year ending December 31, 2024. NOTE: The proxies are authorized to vote in their discretion on such other business as may properly come before the meeting or any adjournment or postponement thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V57512-P18410

    Get the next $NERV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NERV

    DatePrice TargetRatingAnalyst
    3/4/2022$10.00 → $5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $NERV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates

      BURLINGTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the first quarter of 2025 ended on March 31, 2025.    Corporate Update On March 17, 2025, we were formally notified by Nasdaq that we had regained compliance with Nasdaq Listing Rule 5550(b)(3), and as such, will continue to be listed on the Nasdaq Capital Market. Interactions with the FDA continue with the goal of addressing questions raised in the Complete Response Letter (CRL) to our New Drug Application

      5/13/25 7:30:00 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates

      BURLINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended December 31, 2024.    Corporate Update As previously disclosed in the first quarter of 2024, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to our New Drug Application (NDA) for roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company continues to have interactions with the FDA with the goal of addressing

      2/25/25 7:00:00 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates

      BURLINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the third quarter of 2024 ending September 30, 2024.    Roluperidone NDA Update As announced in February 2024, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to our New Drug Application (NDA) for roluperidone (f/k/a MIN-101) for the treatment of negative symptoms in patients with schizophrenia. Interactions with the FDA continue with the goal of addressing questions rais

      11/5/24 7:30:00 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NERV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Kupfer David

      4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)

      12/6/24 5:45:13 PM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Laghrissi-Thode Fouzia

      4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)

      12/6/24 5:45:16 PM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Van Heek G Jan

      4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)

      12/6/24 5:45:18 PM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NERV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Minerva Neurosciences with a new price target

      HC Wainwright & Co. reiterated coverage of Minerva Neurosciences with a rating of Buy and set a new price target of $5.00 from $10.00 previously

      3/4/22 6:14:09 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NERV
    Leadership Updates

    Live Leadership Updates

    See more

    $NERV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Minerva Neurosciences Announces Promotion of Geoff Race to President

      Frederick Ahlholm is Named Chief Financial Officer as Company Prepares to Submit a Pre-NDA Meeting Request to FDA WALTHAM, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that Geoff Race, current Executive Vice President, Chief Financial Officer and Chief Business Officer of Minerva, has been promoted to President. Minerva's Senior Vice President and Chief Accounting Officer, Frederick Ahlholm, has been promoted to Chief Financial Officer. The appointments are effective immediately. These latest leadership

      10/11/21 8:30:00 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research & Development

      WALTHAM, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced Dr. Jay Saoud's retirement and transition to an advisory role and Dr. Ramana Kuchibhatla's appointment as Senior Vice President and Head of Research & Development, both effective September 16, 2021. Dr. Kuchibhatla will report directly to Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva. "I would like to thank Jay for the invaluable skill and leadership which have enabled Minerva to take roluperidone from early stage cl

      9/8/21 8:30:00 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Minerva Neurosciences Inc

      SC 13G/A - Minerva Neurosciences, Inc. (0001598646) (Subject)

      11/12/24 10:32:12 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Minerva Neurosciences Inc

      SC 13G - Minerva Neurosciences, Inc. (0001598646) (Subject)

      2/9/24 9:28:31 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Minerva Neurosciences Inc (Amendment)

      SC 13G/A - Minerva Neurosciences, Inc. (0001598646) (Subject)

      1/18/24 10:21:16 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NERV
    Financials

    Live finance-specific insights

    See more
    • Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates

      BURLINGTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the first quarter ended March 31, 2023. "The first quarter saw the achievement of a significant milestone for our investigational drug, roluperidone, and for Minerva, as the U.S. Food and Drug Administration (FDA) filed our New Drug Application (NDA) for roluperidone for the treatment of negative symptoms of schizophrenia on April 27, 2023. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of

      5/15/23 7:30:00 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023

      BURLINGTON, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release first quarter 2023 financial results and business updates on Monday, May 15, 2023. The Company will host a webcast that day at 8:30 a.m. Eastern Time to discuss the results and updates. The live conference call may be accessed here and on the Company's website under Events and Presentations. The archived webcast will be available on the Company's website beginning approximately two hours after the event for 90 days. About Miner

      5/8/23 8:30:00 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates

      BURLINGTON, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended December 31, 2022. Corporate Update "In 2022, we had multiple interactions with the FDA regarding the regulatory path forward for our lead compound, roluperidone. After submitting an NDA for roluperidone to the FDA in August, we received a Refuse to File letter (RTF) in the fall, which was upheld following another meeting with the FDA. We remain committed to developing roluperid

      3/8/23 7:30:00 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NERV
    SEC Filings

    See more
    • SEC Form 10-Q filed by Minerva Neurosciences Inc

      10-Q - Minerva Neurosciences, Inc. (0001598646) (Filer)

      5/13/25 7:00:34 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Minerva Neurosciences Inc

      10-K/A - Minerva Neurosciences, Inc. (0001598646) (Filer)

      4/28/25 6:46:17 PM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Minerva Neurosciences Inc

      10-K/A - Minerva Neurosciences, Inc. (0001598646) (Filer)

      4/21/25 4:55:27 PM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care